FFM
Fairmount Funds Management Portfolio holdings
AUM
$772M
This Quarter Return
+21.02%
1 Year Return
+35.05%
3 Year Return
+1,168.51%
5 Year Return
+1,432.11%
10 Year Return
–
AUM
$1.23B
AUM Growth
+$1.23B
(+39%)
Cap. Flow
+$138M
Cap. Flow
% of AUM
11.21%
Top 10 Holdings %
Top 10 Hldgs %
87.85%
Holding
17
New
4
Increased
1
Reduced
3
Closed
2
Top Buys
Top Sells
| 1 |
Protagonist Therapeutics
PTGX
|
$32.3M |
| 2 |
Nuvalent
NUVL
|
$24.3M |
| 3 |
BCYC
Bicycle Therapeutics
BCYC
|
$21.4M |
| 4 |
Terns Pharmaceuticals
TERN
|
$5.1M |
| 5 |
Dianthus Therapeutics
DNTH
|
$1.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Axsome Therapeutics
AXSM
$6.05B
| $212M | 17.2% | 2,360,077 | – | – |
|
|
2
Nuvalent
NUVL
$5.52B
| $173M | 13.99% | 1,687,064 -237,562 | -12% | -$24.3M |
|
3
Apogee Therapeutics
APGE
$2.17B
| $120M | 9.76% | 2,048,647 | – | – |
|
4
Spyre Therapeutics
SYRE
$996M
| $118M | 9.58% | 4,018,101 | – | – |
|
5
Enliven Therapeutics
ELVN
$1.2B
| $81.8M | 6.63% | 3,202,798 | – | – |
|
6
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $80.1M | 6.49% | 3,204,841 | – | – |
|
|
ORKA
7
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $78.7M | 6.38% | +3,211,922 | New | +$78.7M |
|
8
Viridian Therapeutics
VRDN
$1.5B
| $78.4M | 6.36% | 3,445,813 +1,600,000 | +87% | +$36.4M |
|
|
9
Dianthus Therapeutics
DNTH
$759M
| $73.9M | 6% | 2,700,691 -62,146 | -2% | -$1.7M |
|
10
Cogent Biosciences
COGT
$1.69B
| $67.2M | 5.45% | 6,225,641 | – | – |
|
11
Day One Biopharmaceuticals
DAWN
$769M
| $43.2M | 3.51% | +3,103,448 | New | +$43.2M |
|
12
Astria Therapeutics
ATXS
$349M
| $39.1M | 3.17% | 3,554,129 | – | – |
|
|
BCAX
13
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $32.7M | 2.65% | +1,284,169 | New | +$32.7M |
|
|
ZBIO
14
Zenas BioPharma, Inc. Common Stock
ZBIO
$674M
| $32M | 2.6% | +1,892,806 | New | +$32M |
|
|
BCYC
15
Bicycle Therapeutics
BCYC
$511M
| $2.8M | 0.23% | 123,538 -945,661 | -88% | -$21.4M |
|
|
16
Protagonist Therapeutics
PTGX
$3.67B
| – | – | -931,890 | Closed | -$32.3M |
|
|
17
Terns Pharmaceuticals
TERN
$609M
| – | – | -748,996 | Closed | -$5.1M |
|